Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00452400 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.

A Phase 2 study of Asthma and Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.

Completed
Registry status
Phase 2
Development phase
409
Enrollment target
20
Study locations

NCT00452400 is a Phase 2 study of Asthma and Pulmonary Disease, Chronic Obstructive that has completed, run by Boehringer Ingelheim. The registered enrollment target is 409 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00452400, a Phase 2 study of Asthma and Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
Phase 2
Development phase
409 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with chronic obstructive pulmonary disease (COPD). The selection of the optimum dose(s) will be based on bronchodilator efficacy (how well it helps your breathing), safety evaluations and pharmacokinetic evaluations (the amount of the medication found in your blood).

Conditions Studied

Asthma Pulmonary Disease, Chronic Obstructive

Interventions

  • DRUG BI 1744CL

Study Locations (20)

Colorado

  • 1222.5.14 Boehringer Ingelheim Investigational Site - Denver
  • 1222.5.13 Boehringer Ingelheim Investigational Site - Wheat Ridge
  • 1222.5.17 Boehringer Ingelheim Investigational Site - Wheat Ridge

South Carolina

  • 1222.5.08 Boehringer Ingelheim Investigational Site - Charleston
  • 1222.5.19 Boehringer Ingelheim Investigational Site - Charleston
  • 1222.5.06 Boehringer Ingelheim Investigational Site - Spartanburg

Pennsylvania

  • 1222.5.05 Boehringer Ingelheim Investigational Site - Hershey
  • 1222.5.02 Boehringer Ingelheim Investigational Site - Philadelphia

Texas

  • 1222.5.21 Boehringer Ingelheim Investigational Site - Kileen
  • 1222.5.01 Boehringer Ingelheim Investigational Site - San Antonio

Alabama

  • 1222.5.03 Boehringer Ingelheim Investigational Site - Birmingham

California

  • 1222.5.07 Boehringer Ingelheim Investigational Site - Lakewood

Connecticut

  • 1222.5.18 Boehringer Ingelheim Investigational Site - Stamford

Florida

  • 1222.5.15 Boehringer Ingelheim Investigational Site - Panama City

Trial Details

FieldValue
Enrollment Target 409 participants
Start Date 2007-03
Phase Phase 2

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00452400

The ClinicalTrials.gov registry entry for NCT00452400 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 409 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (74% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which BI 1744CL is the first listed.

NCT00452400 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Colorado, South Carolina, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00452400 about?

NCT00452400 is a clinical study titled "Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.". The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with chronic obstructive pulmonary disease (COPD). The selection of the optimum dose(s) will be based on bronchodilator efficacy (ho...

What is the current status of trial NCT00452400?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 409 participants. The study started on 2007-03.

What conditions does trial NCT00452400 study?

This clinical trial studies the following conditions: Asthma, Pulmonary Disease, Chronic Obstructive.

What interventions are being tested in trial NCT00452400?

The interventions under investigation include: BI 1744CL (DRUG).

Who is sponsoring clinical trial NCT00452400?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00452400 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

Pulmonary Disease, Chronic Obstructive

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.